Literature DB >> 17189022

Risk in drug trials.

Marc Ohresser, Daniel Olive, Bernard Vanhove, Hervé Watier.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17189022     DOI： 10.1016/S0140-6736(06)69883-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.

Authors:  Manisha Singh; Sreemanti Basu; Christina Camell; Jacob Couturier; Rodolfo J Nudelman; Miguel A Medina; John R Rodgers; Dorothy E Lewis
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

Review 2.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

3.  Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.

Authors:  Nicolas Poirier; Caroline Mary; Stephanie Le Bas-Bernardet; Veronique Daguin; Lyssia Belarif; Melanie Chevalier; Jeremy Hervouet; David Minault; Simon Ville; Vianney Charpy; Gilles Blancho; Bernard Vanhove
Journal:  MAbs       Date:  2014-03-05       Impact factor: 5.857

4.  Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells.

Authors:  Xuehui He; Ruben L Smeets; Esther van Rijssen; Annemieke M H Boots; Irma Joosten; Hans J P M Koenen
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.